MORSCHHAUSER , Franck

Last name: MORSCHHAUSER

First name: Franck

September 19, 2024 (v1)

Journal article

Metadata-only

Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients

Alcantara, Marion Chevrier, Marion Jardin, Fabrice

Background: Results of conventional induction chemotherapies in primary central nervous system lymphoma (PCNSL) need to be improved. Ibrutinib, a BTK inhibitor, and lenalidomide, an immunomodulatory drug, have shown promising results at relapse, supporting to further assess their individual use in combination with high-dose methotrexate-based...

Uploaded on: October 4, 2024
June 2, 2023 (v1)

Conference paper

Metadata-only

Final analysis of the phase IB part of the LOC-R01 trial, a non-comparative randomized phase IB/II study of escalating doses of lenalidomide and ibrutinib in association with R-MPV for patients with a newly diagnosed primary central nervous system lymphoma (PCNSL)

Alcantara, Marion Chevrier, Marion Jardin, Fabrice

International audience

Uploaded on: October 11, 2023
May 2020 (v1)

Journal article

Metadata-only

Early F-FDG PET/CT response predicts survival in Relapsed/Refractory Hodgkin Lymphoma treated with Nivolumab

Chen, Aiping Mokrane, Fatima-Zohra Schwartz, Lawrence

Monoclonal antibodies (mAbs) against programmed cell death 1 (PD-1), such as nivolumab and pembrolizumab, are associated with high response rates in patients with relapsed or refractory classic Hodgkin lymphoma (HL). To date, no prognostic factor for overall survival (OS) has been established with these agents in HL. We examined whether the...

Uploaded on: December 4, 2022
June 2020 (v1)

Journal article

Metadata-only

Performance of CT Compared with F-FDG PET in Predicting the Efficacy of Nivolumab in Relapsed or Refractory Hodgkin Lymphoma

Mokrane, Fatima-Zohra Chen, Aiping Schwartz, Lawrence H

Background CT and fluorine 18 (F) fluorodeoxyglucose (FDG) PET/CT performances following immune therapy are not well known in patients with relapsed or refractory Hodgkin lymphoma (RRHL). Purpose To compare CT and PET/CT for prognostic value of early response evaluation following nivolumab therapy. Materials and Methods This retrospective study...

Uploaded on: December 4, 2022

MORSCHHAUSER , Franck

Recent uploads